Tevogen Bio Holdings Inc. (TVGN) - Total Liabilities
Based on the latest financial reports, Tevogen Bio Holdings Inc. (TVGN) has total liabilities worth $13.62 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TVGN cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Tevogen Bio Holdings Inc. - Total Liabilities Trend (2022–2026)
This chart illustrates how Tevogen Bio Holdings Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TVGN current and non-current assets.
Tevogen Bio Holdings Inc. Competitors by Total Liabilities
The table below lists competitors of Tevogen Bio Holdings Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Francotyp-Postalia Holding AG
F:FPH
|
Germany | €113.20 Million |
|
Rank Progress S.A.
WAR:RNK
|
Poland | zł354.38 Million |
|
Akin Tekstil AS
IS:ATEKS
|
Turkey | TL1.71 Billion |
|
Clene Inc.
NASDAQ:CLNN
|
USA | $47.82 Million |
|
FreeCast, Inc. Class A Common Stock
NASDAQ:CAST
|
USA | $8.12 Million |
|
SMCore.Inc
KQ:007820
|
Korea | ₩54.09 Billion |
|
Carlos Casado
BA:CADO
|
Argentina | AR$18.54 Billion |
|
Senko Co. Ltd
KQ:347000
|
Korea | ₩14.15 Billion |
Liability Composition Analysis (2022–2026)
This chart breaks down Tevogen Bio Holdings Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See TVGN net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tevogen Bio Holdings Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tevogen Bio Holdings Inc. (2022–2026)
The table below shows the annual total liabilities of Tevogen Bio Holdings Inc. from 2022 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $12.62 Million | +24.49% |
| 2025-06-30 | $10.14 Million | -89.86% |
| 2024-06-30 | $99.93 Million | +139.71% |
| 2023-06-30 | $41.69 Million | +72.65% |
| 2022-06-30 | $24.15 Million | -- |
About Tevogen Bio Holdings Inc.
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B… Read more